ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Imatinib, a tyrosine kinase inhibitor which is commonly used in the therapy of chronic myeloid leukaemia (CML) due to its inhibitory action on the chimeric BCR-ABL tyrosine kinase, is also a nonspecific inhibitor of the PDGF receptor and may reverse PH, as demonstrated in an experimental model [129].